Oxcarbazepine

Specifications

28721-07-5CAS Number

249-188-8EC Number

5-oxo-6H-benzo[b][1]benzazepine-11-carboxamideIUPAC Name

C15H12N2O2Chemical Formula

252.27 g/molMolecular Weight

OXCARBAZEPINE; 28721-07-5; Trileptal; Oxcarbamazepine; Oxcarbazepina; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide; Oxcarbazepinum; GP-47680; Oxtellar XR; KIN-493; 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-; 5-oxo-6H-benzo[b][1]benzazepine-11-carboxamide; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; DTXSID0045703; SPN-804; 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide; NSC-758693; OCBZ; CHEBI:7824; VZI5B1W380; 5H-Dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-; 9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide; DTXCID8025703; OX-CBZ; 5-oxo-6H-benzo(b)(1)benzazepine-11-carboxamide; 10-oxo-10,11-dihydro-5H-dibenzo(b,f)azepine-5-carboxamide; 9-oxo-2-azatricyclo(9.4.0.0^(3,8))pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide; RefChem:57861; N03AF02; 9-oxo-2-azatricyclo(9.4.0.03,8)pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide; 249-188-8; GP 47680; MFCD00865307; MLS000084586; CHEMBL1068; SMR000048684; Timox; s1391; NCGC00065934-02; Oxcarbazepine [INN]; M06310; Oxcarbazepinum [INN-Latin]; Oxcarbazepina [INN-Spanish]; Oxcarbazepime; Epilexter; Epliga; Trileptal (TN); CAS-28721-07-5; SR-01000612612; EINECS 249-188-8; UNII-VZI5B1W380; Aurene; Oxcarb;; HSDB 7524; Oxcarbazepine CRS; Oxtellar (TN); Oxcarbazepine [USAN:USP:INN:BAN]; Spectrum_001675; Opera_ID_818; Oxcarbazepine (Standard); regid866068; Spectrum2_000483; Spectrum3_001669; Spectrum4_000634; Spectrum5_001869; O0363; OXCARBAZEPINE [MI]; Epitope ID:423615; OXCARBAZEPINE [JAN]; OXCARBAZEPINE [HSDB]; OXCARBAZEPINE [USAN]; SCHEMBL35129; BSPBio_003457; KBioGR_001248; KBioSS_002155; OXCARBAZEPINE [VANDF]; cid_34312; MLS000759520; MLS001201742; MLS001424025; MLS006011855; BIDD:GT0078; OXCARBAZEPINE [MART.]; SPECTRUM1504243; SPBio_000345; OXCARBAZEPINE [USP-RS]; OXCARBAZEPINE [WHO-DD]; GTPL7254; orb1310614; orb3025230; Oxcarbazepine (JAN/USP/INN); SCHEMBL29359799; SCHEMBL29433241; BDBM34179; HY-B0114R; KBio2_002155; KBio2_004723; KBio2_007291; KBio3_002677; Oxcarbazepine - Bio-X trade mark; Oxcarbazepine, analytical standard; 10,11-Dihydro-10-oxo-5H-dibenzo[b,f]azepine-5-carboxamide; GLXC-07167; HMS1922H17; HMS2051O04; HMS2090F13; HMS2093E10; HMS2231B12; HMS3369J22; HMS3393O04; HMS3657O11; HMS3713I10; HMS3884K13; HMS5079F19; Pharmakon1600-01504243; OXCARBAZEPINE [ORANGE BOOK]; HY-B0114; MSK10264; OXCARBAZEPINE [EP MONOGRAPH]; Tox21_110983; CCG-39509; EBC-03777; NSC758693; OXCARBAZEPINE [USP MONOGRAPH]; STK594696; AKOS005516529; Oxcarbazepine, 1mg/ml in Acetonitrile; Tox21_110983_1; AC-3483; CS-1869; DB00776; FO26622; KS-5197; NC00088; NSC 758693; Oxcarbazepine, >=98% (HPLC), solid; NCGC00065934-03; NCGC00065934-04; NCGC00065934-05; NCGC00065934-06; NCGC00065934-15; BO164187; SY052973; SBI-0206772.P001; GP-47-680; NS00010016; O9210; SW197468-3; T0440; C07492; D00533; EN300-123538; AB00393017-12; AB00393017-14; AB00393017_15; AB00393017_16; Q176301; SR-01000612612-4; SR-01000612612-6; BRD-K04196797-001-12-9; BRD-K04196797-001-23-6; BRD-K04196797-001-24-4; BRD-K04196797-001-25-1; Z1551967555; 10-oxo-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide; 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carbonsaeureamid; 10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide #; Oxcarbazepine Working Standard (Secondary Reference Standard); Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard; Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard; 9-oxo-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide; Oxcarbazepine, Pharmaceutical Secondary Standard; Certified Reference MaterialSynonyms